Search PubMedSearch

Biomedical subjects

J L Henry

Publications and source records attributed to J L Henry.

At least 19 recordsLinked to original sources

Intrathecal administration of non-NMDA receptor agonists increases arterial pressure and heart rate in the rat.

We have found that spinal NMDA receptors are involved in control of sympathetic output in pathways to the heart and vessels. The present study was done to determine whether spinal non-NMDA excitatory amino acid receptors participate in cardiovascular regulation. Experiments were done on urethane-anesthetized Sprague-Dawley rats, giving the non-NMDA receptor agonists, quisqualate and kainate, and the antagonist, kynurenate, intrathecally at the spinal T9 level. Both quisqualate (30 nmol; n = 7; to activate AMPA receptors) and kainate (2 nmol; n = 6; to activate K receptors) increased arterial pressure and heart rate. The responses were characterized by a rapid onset, achieving, in most cases, greater than 80% of the maximum response within 1-4 min, and a persistence throughout the remaining 20-24 min of the experiment. I.v. injection of hexamethonium (10 mg/kg) prevented the effects of intrathecal administration of quisqualate (n = 5) but not of kainate (n = 7). To determine whether the hexamethonium-resistant effects of kainate were due to a peripheral action, kainate was given i.v. (n = 6); it was found to be without effect on arterial pressure or heart rate. The increases in arterial pressure and heart rate produced by intrathecal administration of quisqualate (30 nmol; n = 6), kainate (2 nmol; n = 6), glutamate (1 mumol; n = 6) and NMDA (2 nmol; n = 6) but not carbachol (27.4 nmol; n = 6) were prevented by similar preadministration of kynurenate (125 nmol). Intrathecal administration of kynurenate (125 nmol; n = 6; 500 nmol; n = 7) decreased arterial pressure and/or heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals

NMDA receptor antagonists block cardiovascular responses to intrathecal administration of D-baclofen in the rat.

In previous studies we found that D and L-baclofen have different effects on sympathetic output when administered intrathecally, yet the actions of both enantiomers are blocked by intrathecal administration of phaclofen. The present experiments were done to determine the mechanism by which D-baclofen expresses its effects. In urethane-anaesthetized Sprague-Dawley rats, when D-baclofen was given intrathecally at the T9 spinal level following pretreatment with 2 nmol of the NMDA receptor antagonist, DL-2-amino-5-phosphonovaleric acid (APV), it increased systolic and diastolic arterial pressures (n = 7), as in the previous studies. However, after intrathecal administration of 10 nmol of APV, administration of D-baclofen had no effect on these parameters (n = 7). Intravenous administration of ketamine (7.5 mg/kg), another NMDA receptor antagonist, also blocked the effect of D-baclofen (n = 6) but it had no effect on the pressor responses produced by intrathecal administration of carbachol (27.4 nmol; n = 6). In additional experiments, L-baclofen (70 nmol) had no effect on the increases in heart rate and arterial pressure produced by N-methyl-D-aspartic acid (NMDA) (2 nmol; n = 8). These results indicate that D-baclofen increases arterial pressure via an NMDA receptor-mediated mechanism, perhaps by provoking the release of an endogenous ligand which activates these receptors.

2-Amino-5-phosphonovalerate

Glutamate, NMDA and NMDA receptor antagonists: cardiovascular effects of intrathecal administration in the rat.

Selected excitatory amino acids and antagonists were tested for their effects on arterial pressure and heart rate when administered intrathecally at the second (T2) or ninth (T9) thoracic spinal levels in urethane-anesthetized Sprague-Dawley rats with spontaneous or artificial respiration. Intrathecal administration of glutamate (1 mumol) and N-methyl-D-aspartic acid (NMDA; 2 nmol) at T9 increased arterial pressure and heart rate. The response began within 1 min, peaked at 2-3 min and persisted for 8-15 min. The maximum changes were 20-25 mm Hg for arterial pressure and 40-50 beats/min for heart rate. These responses were prevented by systemic administration of hexamethonium (10 mg/kg). Responses to administration of NMDA at the two spinal levels were essentially the same. Effects elicited by NMDA but not by glutamate were blocked by pretreatment with the NMDA receptor antagonists, D,L-2-amino-5-phosphonovaleric acid (APV; 10 nmol, intrathecal administration) and ketamine (7 mg/kg, i.v.). Intrathecal administration of APV (10, 50 and 200 nmol) at T2 produced dose-dependent decreases in arterial pressure without changing heart rate. The results support the hypothesis that NMDA receptors are involved in regulation of sympathetic output at the spinal level. They also indicate that in this preparation there is a tonic activation of NMDA receptors in sympathetic pathways to the vessels but not to the heart. Finally, the persistence of the response to glutamate in the presence of NMDA receptor antagonists suggests the involvement of non-NMDA receptors in spinal control of sympathetic output.

2-Amino-5-phosphonovalerate

Catecholaminergic depressant effects on bulbar respiratory mechanisms.

On the basis of histochemical and pharmacological studies, catecholamines have been implicated in central mechanisms controlling respiration. This hypothesis was tested in iontophoretic studies on neurones located in bulbar respiratory centres. Adrenaline and noradrenaline had a predominantly depressant effect on respiratory as well as on closely situated non-respiratory units. These depressions were mimicked by the application of isoproterenol and clonidine; acetylcholine and serotonin had inconsistent effects on these neurones. In control experiments, microinjections, using a Hamilton syringe, were made in the area of bulbar respiratory centres: noradrenaline, but not serotonin, depressed the central respiratory activity reflected in the phrenic nerve discharge. These results suggest that specific adrenergic and noradrenergic depressant mechanisms could affect both respiratory and other physiological centres at the bulbar level.

Acetylcholine

Action of narcotic analgesics and antagonists on spinal units responding to natural stimulation in the cat.

Morphine and morphine-related agents were applied by microiontophoresis in the lumbar spinal cord of spinal cats to single units classified on the basis of their responses to natural cutaneous or proprioceptive stimulation. Opiate application had a current-dependent depressant effect on the ongoing activities of about one-third of the units tested. This effect was observed in laminae I and IV--VI, but only with units responding to noxious cutaneous stimuli: the nociceptive responses were themselves depressed. Excitatory and inhibitory responses to glutamate and gamma-aminobutyric acid, respectively, were also depressed. Intravenous administration of the opiates at doses reported to produce analgesia in the cat also depressed only units responding to noxious cutaneous stimuli, including their nociceptive responses. This depression could be reversed by either the iontophoretic application (100 nA) or the intravenous administration (0.1--0.8 mg/kg) of naloxone. These results are interpreted as further evidence that the analgesic effects of opiates are at least partly due to an action at the spinal level.

Action Potentials

Synaptic modulation by substance P.

The phrase "synaptic modulation," to describe a role of neurotropic peptides, has been used in a number of different ways by a number of different investigators. Using the phrase in its original context, i.e. altered (increased or decreased) synaptic excitability without reference to site or mode of action, evidence is presented that substance P modulates synaptic transmission of cat alpha-motoneurons. The effect appears to be biphasic, with low doses inhibiting, and high doses facilitating synaptic transmission.

Melanocyte-Stimulating Hormones

Effect of opioid peptides on L-noradrenaline-stimulated cyclic AMP formation in homogenates of rat cerebral cortex and hypothalamus.

Morphine and the opioid peptides leucine-enkephalin (leu-enk), methionine-enkephalin (met-enk) and beta-endorphin had no effect on basal cyclic AMP levels in rat cerebral cortex and hypothalamus, but each inhibited noradrenaline (NA)-stimulated cyclic AMP formation in both brain regions. This inhibition was reversed by naloxone. Naloxone did not reverse phentolamine- or propranolol-induced inhibition of NA-stimulated cyclic AMP formation. The increase in cyclic AMP formation induced by NaF or MnCl2 was unaffected by met-enk or morphine. These data suggest that in rat cerebral cortex and hypothalamus opiates bind to opiate receptors and that the opiate-receptor complex interferes with noradrenergic receptor activity.

Animals

Antinociceptive effects of intrathecally administered human beta-endorphin in the rat and cat.

Rats chronically implanted with intrathecal catheters displayed a dose-dependent increase in the hot-plate and tail-flick response latencies following the injection of human beta-endorphin into the lumbar spinal subarachnoid space through the indwelling catheter. beta-Endorphin was approximately 25 times more potent than morphine on a molar basis. Matching morphine and beta-endorphin doses such that approximately equal submaximal submaximal effects occurred, it was observed that the antinociception produced by beta-endorphin lasted approximately three times longer than that produced by morphine. Experiments with intrathecal injection of beta-endorphin into the spinal subarachnoid space of cats fitted with intrathecal catheters also revealed a potent antinociceptive effect which was completely antagonized by naloxone. In the rats, naloxone administered systemically in doses of 10--100 microgram/kg produced a parallel shift in the dose-response curves of both nociceptive measures suggesting a competitive antagonism. Using a dose ratio analysis, an in vivo pA2 of 7.1 for naloxone was obtained. These data and those derived from previous work based on the pA2 suggest that the interaction of morphine, certain pentapeptides, and beta-endorphin is the same with regard to the spinal opiate receptor population mediating behaviorally defined analgesia.

Analgesics

Effects of substance P on functionally identified units in cat spinal cord.

A correlation was made between the effects of synthetic substance P (ssP) on spinal dorsal horn neurones and the responses of these neurones to natural peripheral stimulation. It was found that ssP caused excitation only of those units which were excited by noxious radiant heat applied to the skin. ssP also caused a small facilitation of the excitatory response to this noxious stimulus and, in two cases, led to a response to noxious heat of units which had previously been unaffected by this stimulus. The ratio of ssP sensitive to insensitive units was highest in the deeper parts of the dorsal horn. Excitation by ssP showed a positive correlation to excitation by bradykinin. These results suggest that substance P may be involved in excitatory spinal processes and that its actions may be associated specifically with nociception.

Acetylcholine